VoQTLinJKTongLM. Analysis of argatroban and bivalirudin in the management of suspected heparin-induced thrombocytopenia. Ann Pharmacother. 2015;49:178-184.
2.
KeeganSPGallagherEMErnstNEYoungEJMuellerEW. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia. Ann Pharmacother. 2009;43:19-27.
3.
ArpinoPAHalliseyRK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother. 2004;38:25-29.
4.
Verme-GibboneyCNHurstingMJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother. 2003;37:970-975.
5.
ReichertMGMacGregorDAKincaidEHDolinskiSY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother. 2003;37:652-654.
